New data shows Lilly’s Omvoh (mirikizumab-mrkz) delivers corticosteroid-free disease control in ulcerative colitis and deep remission in Crohn’s disease

New composite outcomes data reveal that Lilly’s Omvoh (mirikizumab-mrkz) has achieved significant milestones in treating inflammatory bowel diseases. Patients with ulcerative colitis treated with Omvoh demonstrated comprehensive corticosteroid-free disease control at one year, highlighting the drug’s efficacy and potential to reduce reliance on steroids. Similarly, individuals with Crohn’s disease experienced corticosteroid-free deep remission, showcasing Omvoh’s effectiveness in managing chronic gastrointestinal inflammation. This advancement marks a promising development in the treatment landscape for ulcerative colitis and Crohn’s disease, conditions that affect millions worldwide. The data support Omvoh as a valuable therapeutic option that can improve long-term health outcomes without corticosteroid-associated risks. With these findings, Lilly continues to contribute to innovative solutions that address unmet needs in gastrointestinal care. Patients and healthcare providers may look forward to improved disease management strategies with extended safety profiles.

PR Newswire